Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Melanoma 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 6Carboplatin 6Radiotherapy 5olaparib 4Surveys and Questionnaires 4Cisplatin 4Surgical Procedures, Operative 3Sentinel Lymph Node Biopsy 3Metformin 3pembrolizumab 2lenvatinib 2durvalumab 2dostarlimab 2anlotinib 2Reverse Transcriptase Polymerase Chain Reaction 2Progesterone 2Magnetic Resonance Spectroscopy 2Injections 2High-Energy Shock Waves 2Hematologic Tests 2Genetic Testing 2Docetaxel 2Blood Specimen Collection 2Base Sequence 2Amplified Fragment Length Polymorphism Analysis 2vistusertib 1serabelisib 1pazopanib 1palbociclib 1onapristone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Endometrial Neoplasms × famitinib × Clear all
NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡